This is a summary of the European public assessment report (EPAR) for Azomyr. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Azomyr.
Therapeutic Indication
### Therapeutic indication Azomyr is indicated for the relief of symptoms associated with: - allergic rhinitis (see section 5.1) - urticaria (see section 5.1)
Therapeutic Area (MeSH)
ATC Code
R06AX27
ATC Item
desloratadine
Pharmacotherapeutic Group
Antihistamines for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| desloratadine | N/A | 地氯雷他定 |
EMA Name
Azomyr
Medicine Name
Azomyr
Aliases
N/ANo risk management plan link.
